Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-BAFF CAR-T in Autoimmune Diseases
NCT06279923Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Apr 2024
- Primary completion
- Feb 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19-BAFF targeted CAR T-cells in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), dermatomyositis (DM) and 2 more, sponsored by Zhejiang University. Primary endpoints: Dose-limiting toxicity at 28 years and Incidence of treatment-emergent adverse events at 2 years. Started Apr 2024; status: recruiting.
02
Drugs
CD19-BAFF targeted CAR T-cells
03
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)dermatomyositis (DM)immune-mediated glomerulonephritisneuromyelitis optica (NMO)
Beyond the preview
Go deeper on NCT06279923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06279923.